NCT03430362View on ClinicalTrials.gov

Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 2, 2018

Primary Completion Date

December 23, 2019

Study Completion Date

February 16, 2020

Conditions
Prolonged Labor
Interventions
DRUG

Hyoscine N Butylbromide

7\. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose

DRUG

Normal Saline 0.9%

Group B, will receive 2 ml of normal saline single intravenous dose

Trial Locations (1)

12151

Kasr Alainy medical school, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT03430362 - Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous | Biotech Hunter | Biotech Hunter